---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000037"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-07-16T20:06:13+00:00"
generated_at: "2026-07-16T20:07:05.325513+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inhibrx expands credit facility to $500M with Oxford Finance, receives $100M upfront

## Summary
- Total facility expanded to $500M; $100M funded immediately as Term C Loan, up to $225M more at lenders' discretion.
- Prior to amendment, $175M had been drawn under the original facility.
- Issued warrants to purchase 21,457 shares at $93.21 per share in connection with Term C Loan.
- Proceeds to support clinical development of ozekibart (INBRX-109) and INBRX-106.

## SEC filing metadata
- accession: 0002007919-26-000037
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-07-16T20:06:13+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/0002007919-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/inhibrx-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000037
- JSON: https://secwatch.observer/filing/0002007919-26-000037.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.